CME Group grants 2,864 shares to CCO Winkler

Available on EDGAR 09/17/2026 - 04:29 PM EDT Accepted by SEC EDGAR 09/17/2026 - 04:29 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CME GROUP INC. (CME) reported that Julie Winkler, Sr MD Chief Commercial Officer, received an equity award and related tax withholdings in Common Stock Class A.

On September 15, 2026, she acquired 2,864 shares as a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, 2026, a total of 1,413 shares were surrendered to the issuer to satisfy tax withholding obligations in connection with vesting of previously granted restricted stock. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Winkler Julie

Role Sr MD Chief Commercial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock Class A F2	359	$272.46	$98K
Grant/Award	Common Stock Class A F1	2,864	$275.09	$788K
Tax Withholding	Common Stock Class A F2	373	$275.09	$103K
Tax Withholding	Common Stock Class A F2	361	$275.09	$99K
Tax Withholding	Common Stock Class A F2	320	$275.09	$88K

Holdings After Transaction: Common Stock Class A — 31,561 shares (Direct)

Holdings Before and After: Common Stock Class A, 30,110 to 31,561 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.
2. F2. Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

Key Figures

Restricted stock grant: 2,864 shares Grant price per share: $275.09 per share Shares surrendered for tax withholding: 1,413 shares +2 more

5 metrics

Restricted stock grant 2,864 shares Grant of Common Stock Class A on September 15, 2026 under the CME Group Omnibus Stock Plan

Grant price per share $275.09 per share Price reported for the 2,864-share restricted stock grant on September 15, 2026

Shares surrendered for tax withholding 1,413 shares Total Common Stock Class A surrendered on September 15–16, 2026 to satisfy tax withholding obligations

Tax-withholding price (September 15, 2026) $275.09 per share Applied to 373, 361, and 320 shares surrendered on September 15, 2026

Tax-withholding price (September 16, 2026) $272.46 per share Applied to 359 shares surrendered on September 16, 2026

Key Terms

restricted stock, CME Group Omnibus Stock Plan, tax withholding obligations

3 terms

restricted stock financial

"Represents a grant of restricted stock under the CME Group Omnibus Stock Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

CME Group Omnibus Stock Plan financial

"grant of restricted stock under the CME Group Omnibus Stock Plan, vesting"

tax withholding obligations financial

"satisfy tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity award did CME (CME) report for Julie Winkler?

CME reported that Julie Winkler received a grant of 2,864 shares of Common Stock Class A on September 15, 2026 as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

How many CME (CME) shares were surrendered for taxes in this Form 4?

The filing reports that 1,413 shares of CME Common Stock Class A were surrendered to the issuer to satisfy tax withholding obligations related to the vesting of previously granted restricted stock, through four separate transactions on September 15 and 16, 2026.

Were the CME (CME) insider transactions part of a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for these transactions, meaning the reported grant and tax-withholding share surrenders are not identified as having been executed under a pre-arranged trading plan.

What was the price used for the CME (CME) restricted stock grant to Julie Winkler?

For the September 15, 2026 restricted stock grant of 2,864 shares, the Form 4 reports a price of $275.09 per share for CME Common Stock Class A, consistent across the acquisition and related tax-withholding transactions on that date.

What prices applied to the CME (CME) shares surrendered for tax withholding?

Shares surrendered on September 15, 2026 used a reported price of $275.09 per share for 1,054 shares in aggregate. Shares surrendered on September 16, 2026 used a reported price of $272.46 per share for 359 shares.

What role does Julie Winkler hold at CME (CME) in this Form 4?

Julie Winkler is identified as an officer of CME Group Inc., serving as Sr MD Chief Commercial Officer, and is the reporting person for the equity award and related tax-withholding share surrenders detailed in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winkler Julie

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr MD Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	09/15/2026		A(1)		2,864	A	$275.09	32,974	D
Common Stock Class A	09/15/2026		F(2)		373	D	$275.09	32,601	D
Common Stock Class A	09/15/2026		F(2)		361	D	$275.09	32,240	D
Common Stock Class A	09/15/2026		F(2)		320	D	$275.09	31,920	D
Common Stock Class A	09/16/2026		F(2)		359	D	$272.46	31,561	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

2. Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Julie Winkler	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)